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Background: No Standard treatment options are available for patients with advanced, recurrent or metastatic vulvar
carcinoma not amenable for locoregional treatment.
Patients and methods: In this phase II study, patients with advanced vulvar câncer received paclitaxel (Taxol) every
3 weeks for up to 10 cycles. Primary objective was response rate. Secondary objectives were response duration and
toxicity. Response evaluation was assessed by World Health Organisation criteria, toxicity according to Common
Toxicity Criteria.
Results: Thirty-one women from 10 institutions were included, with a median age of 64 (range 47-84), of which 29
were assessable for response. On study patients received a median of four cycles (range 1 -10). Safety: Grade 3 and 4
neutropenia was seen in eight patients (8/29 = 27.6%), which in one patient resulted in neutropenic fever and
treatment-related death. Further treatment-related grade 3/4 toxicity includes fatigue in three patients (10.3%) and
neuropathy in one patient (3.4%). Efficacy: Overall response was 13.8% (n = 4; two complete responses + two partial
responses). With a median follow-up of 24 months, median PFS was 2.6 months (95%confidence interval 2.04-4.21).
Conclusion: Paclitaxel shows moderate activity for local contrai in advanced vulvar câncer.
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introduction
Carcinoma of the vulva representa ~4% to 5% of
gynaecological malignancies [1]. The annual incidence is 2 per
100 000 women. In 70% of the cases, histology indicates
squamous cell câncer while basal cell câncer, melanoma and
adenocarcinoma allow for the remaining 30%. Vulvar câncer is
a disease of older women as indicated by the median age of 74
years [2].
About 30% of patients present at a clinically late stage of the
disease [2].
The management of early disease is based on surgery,
performing local radical excision and—in case the sentinel
node is positive—proceeding to groin dissection. For more
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advanced disease, surgery combined with radiotherapy or
chemoradiation is the most widely used approach.
Even with multimodality treatment, 40%-50% of patients
with advanced disease will ultimately represent with recurrence
and 40% will die from their disease [3, 4].
Currently, there is no Standard treatment for recurrent
disease. Only in the case of local recurrence is curative surgery,
radiation or chemoradiation possible in ~50% of the patients
[5, 6]. Unfortunately, in the patient group initially presenting
with late-stage disease and a high risk of death of recurrence,
70% of recurrences either present with a regional (groin/pelvis)
or distant component of recurrence [3]. This precludes
radiotherapy as effectiye treatment in this setting. As of today,
there is no effective therapy for the group of patients with
a regional and/or distant recurrence, reflected in a 5-year
survival of <10% [3, 4]. Although chemotherapy hás shown
activity in the neoadjuvant setting with response in up to 60%
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of chemo-naive patients [7-10], both single-agent and
multiagent chemotherapy have shown minimal activity in
(frequently heavily pretreated) recurrent vulvar câncer [11-14].
Single-agent cisplatin, piperazinedione, mitoxantrone or
bleomycin did not result in any objective response or response
duration in recurrent vulvar câncer [12, 13]. There is even less
experience with multiagent chemotherapy in this setting. In
recurrent squamous cell carcinoma of the vulva, we face
a scarcity of data and disappointing results with chemotherapy
[10]. Therapeutic approaches with better response rate and
longer response duration are desperately needed. Paclitaxel is
a cytotoxic agent that stabilizes the tubulin polymer bundles
and therefore interfering with microtubular assembly and cell
replication. It hás broad activity against a number of solid
tumours, including squamous cell carcinomas such as head and
neck and cervical cancers [15-17]. Thus, a phase II trial in
advanced or recurrent vulvar câncer was undertaken. The
three-weekly single-agent schedule was chosen because it
seemed feasible in this older age group.
patients and methods
The study was conducted by the European Organisation for Research and
Treatment of Câncer (EORTC) Gynecological Câncer Group. The protocol
was reviewed and approved by the EORTC Protocol Review Committee
(study number 55985) and the institutional review board of each
participating center. Written informed consent was obtained from ali
patients before registration.
To be eíigible, patients had to meet the following criteria: 18 years of age
or older; histológica! proveu squamous cell carcinoma of the vulva;
measurable [according to World Health Organisation (WHO) criteria [18]]
or evaluable disease not amenable to radiotherapy or surgery as first-line
treatment or measurable metastatic disease outside previously irradiated
áreas or local recurrences within a previously treated área or local lesions
showing progression while on treatment; no prior chemotherapy unless
given as concurrent with radiotherapy; WHO performance less than two or
two and adequate haematological, renal, cardiac and hepatic function.
treatment plan
The study was designed as an open-label, single-arm, multicenter phase II
trial to determine the therapeutic effect of paclitaxel (Taxol, Bristol-Meyers
Squibb, Waterioo, Belgium) in patients with recurrent, metastatic or locally
advanced vulvar câncer not amenable to surgery or radiotherapy. Patients
received paclitaxel 175 mg/m2 i.v. in a three-weekly regimen. Patients
received the Standard premedication for hypersensitivity reactions:
dexamethasone, diphenhydramine and ranitidine for each administration
and antiemetics according to the local institutional Standard.
Toxicity was evaluated according to the National Câncer Institute's
Common Toxicity Criteria for adverse events version 1.0 (Bethesda 1988,
[19]).
No dose escalation was allowed. The paclitaxel dose was reduced for
haematological and non-haematological effects: decrease by one dose levei
to 150 mg/ m2 in case of absolute neutrophil count < 500 lasting for 7 days,
any episode of febrile neutropenia, grade 3 thrombocytopenia, stomatitis or
myalgia. Decrease by two leveis to 135 mg/ m2 was done in case of grade 4
thrombocytopenia.
Patients underwent evaluation of measurable disease every third cycle of
chemotherapy. Response was assessed according to WHO criteria: a 'set of
target lesions' was chosen before the first treatment administration and
measured in their two perpendicular dimensions. Surface área was
calculated by multiplying the two diameters. Lesions were eíigible as target
lesions when they had at least a diameter of 2.5 cm. A complete response
(CR) was defined as complete disappearance of ali known disease,
determined by two observations not less than 4 weeks apart. A partia!
response (PR) was defined as a 50% or more decrease in the sum of tumour
áreas of ali target lesions, determined by two observations not less than 4
weeks apart and no appearance of new lesions or progression of any existing
lesion. In case a 25% or more increase was assessed or a new lesion
appeared, progressive disease was defined. Treatment was continued until
documented disease progression, unacceptable toxicity, patient refusal or in
the case of PR or CR until a maximum of 10 cycles was reached.
statistical considerations
The Simon one-sample two-stage minimax design was applied [20]. A
sample size of 29 assessable patients was required in order to discriminate
between a response rate of 5% and 25% with a type I error = 10% and
a type II error = 5%. Four or more responses needed to be observed for the
treatment to be considered successful.
Patients and characteristics were summarised using appropriate
descriptive statistics. Survival time was calculated from the date of
registration until death from any cause, and surviving patients were
censored at the time of last follow-up. Duration of response was calculated
from the date of treatment start to the date of documented progression. If
a new treatment was started before progression, the duration of response
was censored on the day of start of new treatment. The Kaplan-Meier
method was used to estimate survival and corresponding confidence
intervals (CIs) [21]. These analyses were carried out using SÃS version 8.2
(SÃS Institute,. Cary, NC). Ali eíigible patients are included in the efficacy
analysis while safety data are presented on ali patients who started
protocol treatment regardless of eligibility.
results
patients' characteristics
From February 2001 to December 2004, 31 patients were
registered in the study by 11 institutions. One patient included
in the study did not meet the eligibility criteria because of
a creatinine clearance <60 ml/min and another patient because
of no suitable target lesions. Both patients were excluded from
efficacy analyses. Therefore, 29 eíigible patients were followed
with a median follow-up time of 28 months. Age varied
between 47 and 84 years with a median of 64. Ten patients had
a WHO performance status (PS) of zero, eleven patients a PS
score of one and eight patients of two. At entry, four patients
had locally advanced disease and 22 had locoregional
recurrences, of which eight were with distant metastases. Three
patients had distant metastases only. On study patients received
a median of four cycles (range 1-10).
Baseline characteristics including site of recurrence and prior
therapy are given in Table 1. A total of 42 lesions were assessed
as target lesions. Twelve lesions were located in a prior
irradiation field and eight lesions were previously irradiated.
Twenty-one lesions neither were nor in the previous irradiated
field or previous irradiated. In one lesion, the radiotherapy
status was unknown.
toxicity
One non-eligible patient did not receive any treatment and was
therefore not included in the toxicity evaluation. The remaining
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Table 1. Patients' characteristics (n = 29) Table 2. Toxicity
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Neutropenia 14 (47.6%) 8 (27.6%)
Neutropenic fever 1 (3.3%) 1 (3.3%)
Fatigue 22 (73.3) 3 (10%)
Hemoglobin 29 (96.6%) 2 (6.7%)
Skin toxicity 7 (23.3%) 2 (6.7%)
Oedema 11 (36.7%) 2 (6.7%)
Cardiovascular (arrhytmia) 5 (16.6%) 1 (3.3%)
Thrombosis/embolism 2 (6.7%) 1 (3.3%)
Vomiting 9 (30%) 1 (3.3%)
Other gastrointestinal 14 (46.6%) 1 (3.3%)
Hemorrhage 3 (9.9%) 1 (3.3%)
Neuropathy (sensory) 13 (43.3%) 1 (3.3%)
Arthralgia/myalgia 10 (33.3) 1 (3.3%)
Alopecia 26 (87%) 0
Platelets 1 (3.3%) 0
18 months (range 6-23 months). Three patients had a stable
disease (SD; neither a complete nor a partial response, nor
a progression hás been demonstrated, at least 9 weeks after
treatment start), lasting at least 4 months, resulting in an
overall clinicai benefit of 24%.
The median progression-free survival was 2.6 months (95%
Cl = 2-4.2 months). The progression-free survival rate at 1 year
was 10.3% (95% Cl = 2.6% to 24.3%). The median overall
survival was 6.9 months (95% Cl = 3.52-12.42 months) (Table
3). The 1-year overall survival rate was 31% (95% Cl = 15.2%
to 47.7%) (Figure 1). Five patients still alive at the time of
analysis were censored at the last available date they were
known to be alive.
30 patients received a median of four cycles (range 1-10) of
chemotherapy with a median dose intensity of 99% (range
78%-101%). Four patients discontinued treatment for toxicity.
Three patients did só for neurotoxicity, mainly sensory
neuropathy. One patient (3.3%) experienced a toxic death due
to a grade 4 neutropenia starting at day 6 after the first
administration of chemotherapy. The neutropenia was still
ongoing when on day 22 the patient was hospitalized for fever
with septic shock, and she died the same day. AU toxic effects
are given in Table 2. Most grade 3 and 4 toxic effects were
assessed as mainly related to the chemotherapy. But skin
toxicity and oedema were related to locoregional recurrence.
One patient developed fatal pulmonary embolism while her
disease was rapidly progressive.
response assessment and duration
In two patients out of 29 eligible patients, response could not
be assessed as stipulated by the protocol. One patient died due
to early progression after the second cycle of chemotherapy
before the formal evaluation had taken place and another
patient experienced fatal toxicity (septic shock) after the first
cycle of chemotherapy.
Two patients had a CR and two other a PR, resulting in an
overall response rate of 14%. Median duration of response was
response in relation to rádiotherapy status
In Table 4, the response per target lesion and prior radiation
status are given. Half of the lesions (n = 21) did not receive
rádiotherapy at ali. In three of these lesions (14%), a response
was observed. Twelve lesions occurring in previous irradiated
field did not show any response. On the other hand, in eight
lesions that were irradiated and thereafter had progressed, three
objective responses were seen (37%). It is very well possible that
the site of lesions interferes as a confounding variable. The site
of the lesion can be related both to its radiation status and its
response outcome. Unfortunately, there were not enough data
available to reliably test for such a site interaction. Therefore,
we split the patients in three main groups: primary tumour
lesions, lymph node lesions and other lesions. In Table 5, the
results of this analysis are given. For lesions of primary tumour
origin, previous rádiotherapy appears to correlate with higher
response rates (3/15 = 20% versus 0/5 = 0%). For lymph node
lesions, the relation is reversed: irradiated lesions showed lower
response rates (3/9 = 33.3%'versus 0/3 = 0%).
discussion
The treatment with chemotherapy of recurrent vulvar câncer
after primary surgery and rádiotherapy is neither well defined
nor extensively studied. Due to the low incidence of vulvar
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Table 3. Response to treatment and response duration (n = 29} Table 5. Response per site of lesions and prior radiation status
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Figure 1. Overall survival (OS)
Table 4. Response per prior radiation status
3 AU patients
No RT.at ali ; , 21
Lesions within irradiated field 12
Previous irradiated lesions 8
RT, radiotherapy; CR, complete response; PR, partial response.
câncer, it is difficult to perform randomized trials in this
relatively old age patient group. Cisplatin, bleomycin,
methotrexate, 5-fluorouracil and mitomycin C have shown
considerable activity in a preoperative setting with response
percentages of 60% in chemo-naive patients [7, 8, 22]. Data
about these drugs are scarce in recurrent disease not amenable
to surgery or radiotherapy.
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The current study is the first study on the use of paclitaxel in
recurrent squamous cell câncer of the vulva showing
a moderate response rate of 14%. Paclitaxel is a drug with
antitumour activity in many types of câncer including cervical
câncer [23, 24]. Monotherapy with 175 mg/m2 hás shown to be
a well-tolerated regimen, with boné marrow suppression,
alopecia, náusea and vomiting and peripheral neuropathy being
the most important side-effects. Hypersensitivity reactions
with hypotension and bradycardia can be managed with
premedications like dexamethasone and ranitidine.
Because paclitaxel had not yet been explored in vulvar
câncer, it was chosen as experimental drug in the present study.
Thirty-one patients were able to receive a median of four cycles
with a very acceptable dose intensity of 99% (range 78% to
101%).
The treatment could be given on an outpatient basis and was
well tolerated with neutropenia as most important drug-related
toxicity. However, one patient experienced neutropenic fever in
the very first days after the initial administration. This patient
died during the hospitalization while the neutropenia was
ongoing. She was a 78-year-old woman with no comorbidity or
comedication. Beside age, there was no explanation for the quick
onset and delayed recovery of the neutropenia. Polymorphisms
in the enzyme system responsible for paclitaxel metabolism are
described in the literature and one can speculate that such
a genetic variability might have been responsible for the severe
toxicity in this patient [25]. Other well-known paclitaxel-related
toxic effects, such as fatigue, alopecia, myalgia and sensory
neuropathy, were seen but did not exceed grade 2. Other toxic
effects could be related to the local disease status, like edema,
local infections and skin toxicity.
An objective response rate of 14% was achieved, while in
24% clinicai benefit (CR, PR and SD) was shown. Two women
had a CR, and two had a PR. Especially the PR rate is low in
regard to other studies; however, only 4 of 29 women had
primary locally advanced disease in contrast to 13 of 25 in the
study of Wagenaar [7, 10].
A GOG trial studied monotherapy of low-dose cisplatin every
3 weeks in 24 patients. No objective response was observed. Of
the 22 patients who were assessable for response, no objective
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regression of disease was observed. Ten had SD, while the
remaining 12 had increasing disease. Thirteen other patients who
were deemed ineligible for cisplatin therapy received
piperzinedione. In this group also, no objective response was
assessed [12]. An EORTC phase II investigated three-weekly
combination therapy with bleomycin, methotrexate and CCNU
in irresectable or recurrent vulvar câncer in 25 patients. Twelve
patients with recurrent disease received prior surgery only (n = 9)
or a combination of surgery and irradiation (n = 3). In the latter
group, no responses were observed, while in the surgery-only
group six PRs were seen. Another eight responses (two CRs)
were observed in the group of patients with irresectable disease
who did not receive any other treatment yet [7]. Although the
response rate was encouraging, the toxicity related to
methrotrexate was not acceptable and a modified regimen was
studied in a subsequent EORTC study. Twenty-five patients with
locally advanced or locoregional recurrences entered this phase II
study. The response rate of 56% was again striking but with
major haematological side-effects and mild signs of bleomycin-
related pulmonary toxicity. Two patients died of toxicity. Again
ali patients showing responses only had surgery as previous
treatment. The only patient who was assessable for response after
surgery and radiotherapy showed progressive disease [10].
Prior radiation of target lesions seemed to have impact on
the response rate of lesions, with a response difference between
lesions in previous irradiated field and lesions that were
irradiated before. This is hard to interpret because changes in
vasculature and therewith changes in effect of chemotherapy
are expected to be the same in both groups. Furthermore, there
was a strong suggestion of site interaction. For lesions of
primary tumour origin, previous radiotherapy appears to
correlate with higher response rates while for lymph node
lesions, the relation is reversed: irradiated lesions showed lower
response rates. The available sample is, however, too small to
formally confirm this interaction.
In other squamous tumours, the combination of paclitaxel
and cisplatin or carboplatin hás showed considerable activity.
In recurrent head and neck câncer, the combination resulted in
an objective response of almost 30% [26]. In cervical câncer,
response rates of 30%-50% are demonstrated, with superiority
of combination therapy versus monotherapy [27, 28]. The
combination of paclitaxel and carboplatin in vulvar câncer
might be attractive and should be considered for earlier disease.
In summary, our study shows that paclitaxel can be given
safely on an outpatient basis to patient with locally advanced or
recurrent vulvar câncer, but the low response rate requires
more studies with other cytotoxic or antiangiogenic agents or
combinations.
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